Gender is an age-specific effect modifier for papillary cancers of the thyroid gland.
نویسندگان
چکیده
BACKGROUND Thyroid cancer incidence rates have increased worldwide for decades, although more for papillary carcinomas than other types and more for females than males. There are few known thyroid cancer risk factors except female gender, and the reasons for the increasing incidence and gender differences are unknown. METHODS We used the National Cancer Institute's Surveillance, Epidemiology, and End Results 9 Registries Database for cases diagnosed during 1976-2005 to develop etiological clues regarding gender-related differences in papillary thyroid cancer incidence. Standard descriptive epidemiology was supplemented with age-period-cohort (APC) models, simultaneously adjusted for age, calendar-period and birth-cohort effects. RESULTS The papillary thyroid cancer incidence rate among females was 2.6 times that among males (9.2 versus 3.6 per 100,000 person-years, respectively), with a widening gender gap over time. Age-specific rates were higher among women than men across all age groups, and the female-to-male rate ratio declined quite consistently from more than five at ages 20-24 to 3.4 at ages 35-44 and approached one at ages 80+. APC models for papillary thyroid cancers confirmed statistically different age-specific effects among women and men (P < 0.001 for the null hypothesis of no difference by gender), adjusted for calendar-period and birth-cohort effects. CONCLUSION Gender was an age-specific effect modifier for papillary thyroid cancer incidence. Future analytic studies attempting to identify the risk factors responsible for rising papillary thyroid cancer incidence should be designed with adequate power to assess this age-specific interaction among females and males.
منابع مشابه
Study of correlation between vascular endothelial growth factor receptor and some prognostic factors in papillary carcinoma of thyroid gland
Background and Objective: Thyroid cancer is the most frequent endocrine malignancy in the world and papillary carcinoma is the most frequent thyroid carcinoma. Different markers used for determination of prognosis and VEGFR is one of them. The aim of present study was to determine the expression of Vascular Endothelial Growth Factor Receptor (VEGFR) as a prognostic marker in papillary carcinoma...
متن کاملPapillary Carcinoma of Thyroid Gland in a Patient Treated with Recombinant Growth Hormone
The first successful treatment of growth hormone (GH) deficient children with GH extracted from human pituitary was introduced during late 1950's. The subsequent availability and use of recombinant GH (rhGH) for different clinical conditions raised the question of whether this new therapeutic modality increases the risk of certain conditions such as leukemia or malignancy. Herein, we report o...
متن کاملThyroid Papillary Microcarcinoma: Etiology, Clinical Manifestations, Diagnosis, Follow-up, Histopathology and Prognosis
Background: Thyroid carcinoma is the most common malignancy of the endocrine system. Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, accounting for 70–90% of well-differentiated thyroid malignancies. Thyroid papillary microcarcinoma is a subtype of papillary carcinoma that included tumors with less than 10mm diameter. As a result of diagnostic methods improvement, p...
متن کاملEctopic papillary thyroid carcinoma in the mediastinum without any tumoral involvement in the thyroid gland. A Case report
Ectopic thyroid tissue results from abnormal embryologic development and migration of the thyroid gland. True malignant transformation in ectopic thyroid tissue is extremely rare and is always diagnosed after surgical excision of the lesion by pathology examinations. There are well-documented cases of ectopic thyroid cancer while primary tumoral lesion occurs in the orthotopic thyroid, but only...
متن کاملAn Unusual Case Report: Occurrence of Renal Cell Carcinoma, Basal Cell Carcinoma and Chronic Lymphocytic Leukemia in a Case of Papillary Thyroid Carcinoma Treated with Radioactive Iodine
The standard therapy for thyroid cancer is total or near total thyroidectomy, followed by the administration of radioactive iodine for remnant ablation or residual disease. Patients with radioiodine therapy are predisposed to second malignant neoplasms in organs such as central nervous system (CNS), breast, prostate, kidney, bone marrow, salivary gland, and digestive tract. Exposure to carcinog...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
دوره 18 4 شماره
صفحات -
تاریخ انتشار 2009